Status: Recruiting
AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
This is an open-label, multi-center Phase 1b clinical study of oral AS-1763 (docirbrutinib) in patients with CLL/SLL or B-cell NHL who have failed or are intolerant to ≥2 lines of systemic therapy.
Participants needed: 120
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Carna Biosciences, Inc.Updated: Dec 10, 2025Locations: 13
Eligibility criteria
Age ≥18 years [+12]
Transformed disease (eg, Richter's transformation) prior to or during Screening [+23]